Al Roy, Executive Director of Lupus Research Alliance affiliate Lupus Therapeutics, speaks to the importance of diversity in lupus clinical trials. Without diversity in clinical trials drug efficacy cannot be assured for all and treatment options will be limited for many lupus patients.